BioNTech SE ADR closed $17.54 below its 52-week high ($131.49), which the company achieved on September 17th.

The ADR's fall snapped a three-day winning streak.

Geode Capital Management LLC trimmed its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 0.8% during the 3rd quarter, ...

BioNTech SE (NASDAQ:BNTX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seventeen ...

BioNTech SE has reached a settlement agreement with the University of Pennsylvania over a royalty dispute related to its COVID-19 vaccine, developed in collaboration with Pfizer. The agreement ...

BioNTech SE ( (BNTX) ) has provided an update. BioNTech SE has settled a dispute with the National Institutes of Health (NIH) regarding royalties allegedly owed on sales of its COVID-19 vaccine, ...

Analyst Akash Tewari from Jefferies maintained a Buy rating on BioNTech SE (BNTX – Research Report) and keeping the price target at ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioNTech SE (BNTX – Research Report), Vertex Pharmaceuticals ...

Pfizer has also agreed to reimburse BioNTech for part of these royalties. More about BioNTech SE BioNTech SE is a biotechnology company primarily focused on developing and manufacturing ...

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor ...

Dec 13 (Reuters) - BioNTech SE (22UAy.DE), opens new tab said on Friday it has been informed by its partner OncoC4 that the U ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...